Characterization of nanoparticles for vaccine development

Autores
Rizzo, Gastón; Smaldini, Paola; Herrera, Santiago; Agazzi, Maximiliano; Cortez, Lorena; Azzaroni, Omar; Docena, Guillermo
Año de publicación
2019
Idioma
inglés
Tipo de recurso
documento de conferencia
Estado
versión publicada
Descripción
Nanotechnology are becoming to play an important role in vaccine development, it offers the opportunity to design nanoparticles varying in composition, size, shape and surface properties for application in the fields of medicine. In this work, we aimed to characterize nanoparticles as a safety adjuvant for further use in immunotherapies. Polycationic polymer nanoparticles (R3N0) were used in BMDC to characterize them in vitro. Nanoparticle-cell interaction (internalization or adhesion) was evaluated by microscopy and cell phenotype activation (MHCII and CD86) were determined by flow-cytometry. IL-1β-production was also evaluated by ELISA. Furthermore, Balb/c mice were intraperitoneally sensitized with R3N0, R3N0 plus OVA (combined) and OVA conjugated to R3N0. Finally, humoral (serum antibodies) and cellular immune response (cytokines) was evaluated by ELISA and flow cytometry. We found that R3N0 is internalized by the cells generating its activation with an increase in the expression of CD86 and IL-1β. In turn, R3N0 promotes grater stimulation and release of IL-1β than the positive control (P<0.05). IL-1β was abrogated by the presence of inhibitors of the pathways that activate the inflammosome NLRP3. In vivo, we observed that the OVA-specific-IgG levels were much higher than those corresponding to the adjuvant used as a positive control (P<0.05). Immunized mice showed an increase of IFN-γ by LTCD4 and LTCD8. In conclusion, we found that R3N0 are internalized by BMDC and activates them with the production of proinflammatory cytokines. Moreover, this nanoparticle may have a potential adjuvant effect with the production of Th1 specific antibodies and an IFN-γ dependent cell response.
Materia
Ciencias Químicas
Nanotechnology
nanoparticles
Nanoparticle-cell interaction
inflammosome NLRP3
Nivel de accesibilidad
acceso abierto
Condiciones de uso
http://creativecommons.org/licenses/by-nc-nd/4.0/
Repositorio
CIC Digital (CICBA)
Institución
Comisión de Investigaciones Científicas de la Provincia de Buenos Aires
OAI Identificador
oai:digital.cic.gba.gob.ar:11746/10411

id CICBA_9e19d71e27d5cd9bbb0b35c698b83b18
oai_identifier_str oai:digital.cic.gba.gob.ar:11746/10411
network_acronym_str CICBA
repository_id_str 9441
network_name_str CIC Digital (CICBA)
spelling Characterization of nanoparticles for vaccine developmentRizzo, GastónSmaldini, PaolaHerrera, SantiagoAgazzi, MaximilianoCortez, LorenaAzzaroni, OmarDocena, GuillermoCiencias QuímicasNanotechnologynanoparticlesNanoparticle-cell interactioninflammosome NLRP3Nanotechnology are becoming to play an important role in vaccine development, it offers the opportunity to design nanoparticles varying in composition, size, shape and surface properties for application in the fields of medicine. In this work, we aimed to characterize nanoparticles as a safety adjuvant for further use in immunotherapies. Polycationic polymer nanoparticles (R3N0) were used in BMDC to characterize them in vitro. Nanoparticle-cell interaction (internalization or adhesion) was evaluated by microscopy and cell phenotype activation (MHCII and CD86) were determined by flow-cytometry. IL-1β-production was also evaluated by ELISA. Furthermore, Balb/c mice were intraperitoneally sensitized with R3N0, R3N0 plus OVA (combined) and OVA conjugated to R3N0. Finally, humoral (serum antibodies) and cellular immune response (cytokines) was evaluated by ELISA and flow cytometry. We found that R3N0 is internalized by the cells generating its activation with an increase in the expression of CD86 and IL-1β. In turn, R3N0 promotes grater stimulation and release of IL-1β than the positive control (P&lt;0.05). IL-1β was abrogated by the presence of inhibitors of the pathways that activate the inflammosome NLRP3. In vivo, we observed that the OVA-specific-IgG levels were much higher than those corresponding to the adjuvant used as a positive control (P&lt;0.05). Immunized mice showed an increase of IFN-γ by LTCD4 and LTCD8. In conclusion, we found that R3N0 are internalized by BMDC and activates them with the production of proinflammatory cytokines. Moreover, this nanoparticle may have a potential adjuvant effect with the production of Th1 specific antibodies and an IFN-γ dependent cell response.2019-10-10info:eu-repo/semantics/conferenceObjectinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_5794info:ar-repo/semantics/documentoDeConferenciaapplication/pdfhttps://digital.cic.gba.gob.ar/handle/11746/10411enginfo:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-nd/4.0/reponame:CIC Digital (CICBA)instname:Comisión de Investigaciones Científicas de la Provincia de Buenos Airesinstacron:CICBA2025-09-29T13:40:03Zoai:digital.cic.gba.gob.ar:11746/10411Institucionalhttp://digital.cic.gba.gob.arOrganismo científico-tecnológicoNo correspondehttp://digital.cic.gba.gob.ar/oai/snrdmarisa.degiusti@sedici.unlp.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:94412025-09-29 13:40:03.611CIC Digital (CICBA) - Comisión de Investigaciones Científicas de la Provincia de Buenos Airesfalse
dc.title.none.fl_str_mv Characterization of nanoparticles for vaccine development
title Characterization of nanoparticles for vaccine development
spellingShingle Characterization of nanoparticles for vaccine development
Rizzo, Gastón
Ciencias Químicas
Nanotechnology
nanoparticles
Nanoparticle-cell interaction
inflammosome NLRP3
title_short Characterization of nanoparticles for vaccine development
title_full Characterization of nanoparticles for vaccine development
title_fullStr Characterization of nanoparticles for vaccine development
title_full_unstemmed Characterization of nanoparticles for vaccine development
title_sort Characterization of nanoparticles for vaccine development
dc.creator.none.fl_str_mv Rizzo, Gastón
Smaldini, Paola
Herrera, Santiago
Agazzi, Maximiliano
Cortez, Lorena
Azzaroni, Omar
Docena, Guillermo
author Rizzo, Gastón
author_facet Rizzo, Gastón
Smaldini, Paola
Herrera, Santiago
Agazzi, Maximiliano
Cortez, Lorena
Azzaroni, Omar
Docena, Guillermo
author_role author
author2 Smaldini, Paola
Herrera, Santiago
Agazzi, Maximiliano
Cortez, Lorena
Azzaroni, Omar
Docena, Guillermo
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Ciencias Químicas
Nanotechnology
nanoparticles
Nanoparticle-cell interaction
inflammosome NLRP3
topic Ciencias Químicas
Nanotechnology
nanoparticles
Nanoparticle-cell interaction
inflammosome NLRP3
dc.description.none.fl_txt_mv Nanotechnology are becoming to play an important role in vaccine development, it offers the opportunity to design nanoparticles varying in composition, size, shape and surface properties for application in the fields of medicine. In this work, we aimed to characterize nanoparticles as a safety adjuvant for further use in immunotherapies. Polycationic polymer nanoparticles (R3N0) were used in BMDC to characterize them in vitro. Nanoparticle-cell interaction (internalization or adhesion) was evaluated by microscopy and cell phenotype activation (MHCII and CD86) were determined by flow-cytometry. IL-1β-production was also evaluated by ELISA. Furthermore, Balb/c mice were intraperitoneally sensitized with R3N0, R3N0 plus OVA (combined) and OVA conjugated to R3N0. Finally, humoral (serum antibodies) and cellular immune response (cytokines) was evaluated by ELISA and flow cytometry. We found that R3N0 is internalized by the cells generating its activation with an increase in the expression of CD86 and IL-1β. In turn, R3N0 promotes grater stimulation and release of IL-1β than the positive control (P&lt;0.05). IL-1β was abrogated by the presence of inhibitors of the pathways that activate the inflammosome NLRP3. In vivo, we observed that the OVA-specific-IgG levels were much higher than those corresponding to the adjuvant used as a positive control (P&lt;0.05). Immunized mice showed an increase of IFN-γ by LTCD4 and LTCD8. In conclusion, we found that R3N0 are internalized by BMDC and activates them with the production of proinflammatory cytokines. Moreover, this nanoparticle may have a potential adjuvant effect with the production of Th1 specific antibodies and an IFN-γ dependent cell response.
description Nanotechnology are becoming to play an important role in vaccine development, it offers the opportunity to design nanoparticles varying in composition, size, shape and surface properties for application in the fields of medicine. In this work, we aimed to characterize nanoparticles as a safety adjuvant for further use in immunotherapies. Polycationic polymer nanoparticles (R3N0) were used in BMDC to characterize them in vitro. Nanoparticle-cell interaction (internalization or adhesion) was evaluated by microscopy and cell phenotype activation (MHCII and CD86) were determined by flow-cytometry. IL-1β-production was also evaluated by ELISA. Furthermore, Balb/c mice were intraperitoneally sensitized with R3N0, R3N0 plus OVA (combined) and OVA conjugated to R3N0. Finally, humoral (serum antibodies) and cellular immune response (cytokines) was evaluated by ELISA and flow cytometry. We found that R3N0 is internalized by the cells generating its activation with an increase in the expression of CD86 and IL-1β. In turn, R3N0 promotes grater stimulation and release of IL-1β than the positive control (P&lt;0.05). IL-1β was abrogated by the presence of inhibitors of the pathways that activate the inflammosome NLRP3. In vivo, we observed that the OVA-specific-IgG levels were much higher than those corresponding to the adjuvant used as a positive control (P&lt;0.05). Immunized mice showed an increase of IFN-γ by LTCD4 and LTCD8. In conclusion, we found that R3N0 are internalized by BMDC and activates them with the production of proinflammatory cytokines. Moreover, this nanoparticle may have a potential adjuvant effect with the production of Th1 specific antibodies and an IFN-γ dependent cell response.
publishDate 2019
dc.date.none.fl_str_mv 2019-10-10
dc.type.none.fl_str_mv info:eu-repo/semantics/conferenceObject
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_5794
info:ar-repo/semantics/documentoDeConferencia
format conferenceObject
status_str publishedVersion
dc.identifier.none.fl_str_mv https://digital.cic.gba.gob.ar/handle/11746/10411
url https://digital.cic.gba.gob.ar/handle/11746/10411
dc.language.none.fl_str_mv eng
language eng
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:CIC Digital (CICBA)
instname:Comisión de Investigaciones Científicas de la Provincia de Buenos Aires
instacron:CICBA
reponame_str CIC Digital (CICBA)
collection CIC Digital (CICBA)
instname_str Comisión de Investigaciones Científicas de la Provincia de Buenos Aires
instacron_str CICBA
institution CICBA
repository.name.fl_str_mv CIC Digital (CICBA) - Comisión de Investigaciones Científicas de la Provincia de Buenos Aires
repository.mail.fl_str_mv marisa.degiusti@sedici.unlp.edu.ar
_version_ 1844618596706156544
score 13.070432